Page last updated: 2024-08-21

pyrazines and p276-00

pyrazines has been researched along with p276-00 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anderson, KC; Carrasco, R; Chabner, B; Chauhan, D; Chhetri, S; Cirstea, D; Hideshima, T; Ikeda, H; Kiziltepe, T; Mitsiades, C; Mukherjee, S; Munshi, NC; Okawa, Y; Parikh, H; Podar, K; Pozzi, S; Raab, M; Raje, N; Richardson, PG; Rooney, M; Scadden, D; Sharma, S; Vallet, S	1
Joshi, KS; Manohar, SM; Shirsath, NP	1

Other Studies

2 other study(ies) available for pyrazines and p276-00

Article	Year
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia, 2009, Volume: 23, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Marrow; Boronic Acids; Bortezomib; Caspases; Cell Adhesion; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor Proteins; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Flavones; Gene Expression Profiling; Humans; Insulin-Like Growth Factor I; Interleukin-6; Male; Mice; Mice, SCID; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Pyrazines; Retinoblastoma Protein; Stromal Cells; Transplantation, Heterologous; Tumor Cells, Cultured	2009
P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines. Molecular cancer, 2012, Oct-18, Volume: 11 Topics: Animals; Antigens, Surface; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cyclin D1; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Flavones; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrazines; RNA, Small Interfering; Survival Analysis; Xenograft Model Antitumor Assays	2012

Article

Year

Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.

Leukemia, 2009, Volume: 23, Issue:5

Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Marrow; Boronic Acids; Bortezomib; Caspases; Cell Adhesion; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor Proteins; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Flavones; Gene Expression Profiling; Humans; Insulin-Like Growth Factor I; Interleukin-6; Male; Mice; Mice, SCID; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Pyrazines; Retinoblastoma Protein; Stromal Cells; Transplantation, Heterologous; Tumor Cells, Cultured

2009

P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.

Molecular cancer, 2012, Oct-18, Volume: 11

Topics: Animals; Antigens, Surface; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cyclin D1; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Flavones; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lymphoma, Mantle-Cell; Mice; Mice, SCID; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrazines; RNA, Small Interfering; Survival Analysis; Xenograft Model Antitumor Assays

2012